Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Learn where to report crypto gains on your tax return in 2026, including which forms and sections apply to different transaction types.
24,332 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Two tech giants sit at the edge of unprecedented scale. This article weighs Nvidia and Alphabet's growth engines, eva...
If you’re exploring how to invest in ETFs 2026, you’re not alone. This guide breaks down practical, actionable steps ...
Two travel giants—Vail Resorts and Viking Holdings—represent different bets on leisure demand. This analysis compares...
GE Vernova surprised investors with strong momentum in the first half of 2026. This article breaks down what powered ...
As the infrastructure megatrend gathers steam, a single ETF could anchor your 2026 strategy. Learn which fund stands ...
Oracle’s 2026 story blends a sharp stock pullback with strong earnings momentum. Learn what’s driving the 18% drop, w...
Hydrogen policy momentum and rising costs are shaping a wide range of outcomes for plug power (plug) stock, with anal...
Hess Midstream’s capital return program is under review as a $60 million buyback coincides with a high payout ratio a...
Markets have pulled back in 2026, testing nerves and plans. This guide helps long-term investors stay focused, avoid ...
As investors pivot away from high-flying tech, the financial sector could offer underappreciated value. This guide ex...
As the SaaS crowd sinks, AI-powered software names may rise to the occasion in 2026. This article explains why and po...